Skip Navigation
Find a Doctor


Photo of Dr. Jenny Jiyun Kim, MD MS

Jenny Jiyun Kim, MD MS

Assistant Professor of Oncology
Appointment Phone


Main Location

Johns Hopkins Sidney Kimmel Comprehensive Cancer Center

View All Locations
Out-of-State & International Patients +
Out of State Patients

Call 410-464-6641 (8a.m. to 6p.m., EST, Mon-Fri)

Learn more about our out-of-state patient services »

International Patients

Call +1-410-502-0773 (7a.m. to 6p.m., EST, Mon-Fri)

Learn more about our international patient services »


  • Assistant Professor of Oncology

Centers & Institutes

  • Sidney Kimmel Comprehensive Cancer Center


Bladder Cancer, Kidney Cancer, Medical Oncology, Urological Oncology

Research Interests

prostate cancer; bladder cancer; kidney cancer; testicular cancer; urothelial cancers; genetic polymorphisms


Dr. Kims research is focused on translational research projects and clinical trials in renal cell cancer. Her research aims encompass discovering predictive as well as prognostic blood and tissue based biomarkers which can be applied in the clinical management of renal cell cancer patients. Dr. Kim also leads the renal cell cancer program development at Johns Hopkins. She completed her medical training and residency at University of Southern California and hematology and medical oncology fellowship at The Cleveland Clinic. She is board certified in internal medicine and medical oncology and has a growing clinic for patients with kidney cancer and bladder cancer.


  • English
  • Korean

Clinical Trial Keywords

  • kidney cancer
  • urothelial cancers

Additional Resources

Additional Resources +
  • Education +


    • University of Southern California Keck School of Medicine (Los Angeles CA) (2004)


    • University of Southern California Medical Center / Internal Medicine (Los Angeles CA) (2007)


    • Cleveland Clinic / Hematology and Oncology (Cleveland OH) (2010)


    • American Board of Internal Medicine / Medical Oncology (2010)
    • American Board of Internal Medicine / Internal Medicine (2007)
  • Research & Publications +

    Selected Publications

    1. George S, Pili R, Carducci MA, Kim JJ. The Role of Immunotherapy in Advanced Renal Cell Carcinoma. Submitted to JNCCN

    2. Kim JJ, Vaziri SA, Rini BI, Elson P, Garcia JA, Wirka R, Dreicer R, Ganapathi MK, Ganapathi, R. Association of VEGF and VEGFR2 Single Nucleotide Polymorphisms with Hypertension and Clinical Outcome in Metastatic Clear Cell Renal Cell Carcinoma Patients Treated With Sunitinib. Published online Aug 2011. Cancer

    3. Kim JJ, Keizman D, Denmeade SR, Antonarakis ES. The unfolding treatment landscape for men with castration-resistant prostate cancer. Clin. Invest. 2011 1(11), 1533-1544

    4. Chaux A, Schultz L, Albadine R, Hicks J, Kim JJ, Allaf ME, et al. "Immunoexpression Status and Prognostic Value of mTOR and Hypoxia-Induced Pathway Members in Papillary Cell Renal Cell Carcinomas. American Journal of Surgical Pathology. Accepted.

    5. Schultz L, Chaux A, Albadine R, Hicks, J, Kim JJ, De Marzo AM, Allaf ME, Carducci MA, Rodriguez R, Hammers H, Argani P, Reuter VE, Netto GJ. Immunoexpression Status and Prognostic Value of mTOR and Hypoxia-induced Pathway Members in Primary and Metastatic Clear Cell Renal Cell Carcinomas. Am. J. Surg. Pathology 2011; 35(10):1549-56.

    6. Keijman D. Huang P. Eisenberger MA, Pili R, Kim JJ, Antonarakis ES, Hammers H, Carducci MA. Angiotensin system inhibitors and outcome of sunitinib treatment in patients with metastatic renal cell carcinioma: A retrospective examination. Eur J Cancer 2011 May18 [Epub ahead of print]

    7. Keizman D, Huang P, Antonarakis ES, Sinibaldi V, Carducci MA, Denmeade S, Kim JJ, WalczakJ, Eisenberger MA. The change of PSA doubling time and its association with disease progression in patients with biochemically relapsed prostate cancer treated with intermittent androgen deprivation. Prostate. 2011 Mar 22 [Epub ahead of print].

    8. Kim JJ, Redman B. Chapter 15. Kidney Cancer: Tumor Board Review Guideline and Case Reviews in Oncology. Demos Medical 2011

    9. SA Vaziri, Kim JJ, MK Ganapathi, R Ganapathi. VEGF Polymorphisms: role in Response and Toxicity of TKIs. Current Oncology Reports. 2010; 12(2): 102-108

    10. Kim JJ, Rini BI, Hansel DE. Von Hippel Lindau Syndrome. Adv. Exp. Med. Biol. 2010;685:228-49.

    11. Kim JJ, BI Rini. Recent advances in molecularly targeted therapy in advanced renal cell carcinoma. Therapy. 2009; 6(3): 309-320

    12. Hangai M. Kitaya N. Xu J. Chan CK. Kim JJ. Werb Z. Ryan SJ. Brooks PC. Matrix metalloproteinase-9-dependent exposure of a cryptic migratory control site in collagen is required before retinal angiogenesis. American Journal of Pathology. 2002; 161(4):1429-37

    13. Xu J. Rodriguez D. Petitclerc E. Kim JJ. Hangai M. Moon YS. Davis GE. Brooks PC. Proteolytic exposure of a cryptic site within collagen type IV is required for angiogenesis and tumor growth in vivo. Journal of Cell Biology. 2001; 154(5):1069-79

  • Academic Affiliations & Courses +
  • Activities & Honors +
  • Videos & Media +
  • Events +
  • Contact & Locations +


    Johns Hopkins Sidney Kimmel Comprehensive Cancer Center
    401 N. Broadway
    Baltimore, MD 21231
    Phone: 410-614-0682
    Appointment Phone: 410-955-8964
    Location Map


    • Oncology

Is This You? Edit Profile


© The Johns Hopkins University, The Johns Hopkins Hospital, and Johns Hopkins Health System. All rights reserved.

Privacy Policy and Disclaimer